Bristol Myers Squibb Company (BMY) To Go Ex-Dividend on April 2nd

Bristol Myers Squibb Company (NYSE:BMY) announced a quarterly dividend on Monday, March 2nd. Shareholders of record on Thursday, April 2nd will be given a dividend of 0.63 per share by the biopharmaceutical company on Friday, May 1st. This represents a c) annualized dividend and a dividend yield of 4.2%. The ex-dividend date of this dividend is Thursday, April 2nd.

Bristol Myers Squibb has increased its dividend by an average of 0.0%annually over the last three years and has raised its dividend every year for the last 17 years. Bristol Myers Squibb has a payout ratio of 41.5% indicating that its dividend is sufficiently covered by earnings. Analysts expect Bristol Myers Squibb to earn $6.09 per share next year, which means the company should continue to be able to cover its $2.52 annual dividend with an expected future payout ratio of 41.4%.

Bristol Myers Squibb Stock Performance

Shares of BMY opened at $59.76 on Tuesday. Bristol Myers Squibb has a 12-month low of $42.52 and a 12-month high of $62.89. The company has a current ratio of 1.26, a quick ratio of 1.14 and a debt-to-equity ratio of 2.32. The company has a market cap of $122.01 billion, a PE ratio of 17.32, a price-to-earnings-growth ratio of 0.17 and a beta of 0.26. The stock has a 50-day moving average price of $58.91 and a 200-day moving average price of $52.35.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The company had revenue of $12.50 billion during the quarter, compared to the consensus estimate of $12.24 billion. During the same quarter last year, the company posted $1.67 earnings per share. The firm’s revenue for the quarter was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities analysts forecast that Bristol Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bristol Myers Squibb

A number of large investors have recently modified their holdings of BMY. Vanguard Group Inc. boosted its position in Bristol Myers Squibb by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 198,727,768 shares of the biopharmaceutical company’s stock valued at $10,719,376,000 after acquiring an additional 2,743,759 shares in the last quarter. State Street Corp raised its position in shares of Bristol Myers Squibb by 1.4% in the 4th quarter. State Street Corp now owns 97,980,438 shares of the biopharmaceutical company’s stock worth $5,285,065,000 after acquiring an additional 1,385,206 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Bristol Myers Squibb by 13.1% in the 4th quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock valued at $2,837,026,000 after purchasing an additional 6,084,046 shares during the period. Norges Bank bought a new stake in shares of Bristol Myers Squibb during the fourth quarter valued at approximately $1,947,272,000. Finally, Ameriprise Financial Inc. grew its stake in Bristol Myers Squibb by 1.3% in the second quarter. Ameriprise Financial Inc. now owns 32,579,618 shares of the biopharmaceutical company’s stock worth $1,508,099,000 after purchasing an additional 432,158 shares during the period. Institutional investors own 76.41% of the company’s stock.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.